Graduate Program in Pharmaceutical Sciences, Federal University of Sergipe, Avenue Marechal Rondon, Jd. Rosa Elze, São Cristóvão, 49100-000, Sergipe, Brazil.
Laboratory of Teaching and Research in Social Pharmacy (LEPFS), Department of Pharmacy, Federal University of Sergipe, Avenue Marechal Rondon, Jd. Rosa Elze, 49100-000, São Cristóvão, Sergipe, Brazil.
Sci Rep. 2024 Oct 3;14(1):22979. doi: 10.1038/s41598-024-74559-2.
One of the measures for monitoring microbial resistance is the calculation of the defined daily dose of antimicrobial agents. For this calculation, the weight of an adult of 70 kg is used as a standard, so that application in neonatology is not possible. The aim of this study is to describe the use profile and calculate the defined daily dose (DDD) of antimicrobials in a neonatal intensive care unit (NICU) of a public hospital in the interior of Bahia, Brazil. From March 2020 to December 2021, the medical records of 712 newborns admitted to a NICU between September 2018 and June 2020 were analyzed. A total of 410 newborns diagnosed with neonatal sepsis were included. The most used antimicrobials per patient were gentamicin (408/410; 99.5%), ampicillin (407; 99.3%), amikacin (29; 7.1%) and oxacillin (21; 5.1%), with a mean (SD) treatment duration of 9.8 (3.9) days. The most commonly used combination of antimicrobials was ampicillin with gentamicin, which was used in 406 patients (99.0%). The values for neonatal DDDs were on average 26 times lower than those for adult DDDs. The neonatal DDDs were similar to those observed in other studies. Ampicilin and cefepime were the antimicrobials for which the greatest differences were observed in neonatal DDDs compared with adult DDDs, which differed mainly between maintenance doses, reflecting the lack of international standards in neonatology. Standardization of DDDs as a surveillance measure has the potential to clarify the pattern of antimicrobial use in neonatal patients worldwide and, in particular, to prevent indiscriminate use and bacterial resistance.
监测微生物耐药性的措施之一是计算抗菌药物的限定日剂量。为此计算,使用 70kg 成人标准体重,因此新生儿不能使用该方法。本研究旨在描述巴西巴伊亚州一家公立医院新生儿重症监护病房(NICU)的抗菌药物使用情况并计算其限定日剂量(DDD)。2020 年 3 月至 2021 年 12 月,分析了 2018 年 9 月至 2020 年 6 月间入住 NICU 的 712 名新生儿的病历。共纳入 410 名诊断为新生儿败血症的新生儿。每位患者使用最多的抗菌药物分别为庆大霉素(408/410;99.5%)、氨苄西林(407;99.3%)、阿米卡星(29;7.1%)和苯唑西林(21;5.1%),平均(SD)治疗时间为 9.8(3.9)天。最常用的抗菌药物组合为氨苄西林联合庆大霉素,有 406 名患者(99.0%)使用。新生儿 DDD 平均比成人 DDD 低 26 倍。新生儿 DDD 与其他研究观察到的结果相似。与成人 DDD 相比,新生儿 DDD 中观察到的氨苄西林和头孢吡肟差异最大,主要差异在于维持剂量,反映了新生儿科缺乏国际标准。将 DDD 作为监测措施标准化有可能阐明全球新生儿患者抗菌药物使用模式,特别是防止滥用和细菌耐药性。